Amova Asset Management Americas Inc. Sells 1,702,683 Shares of Adaptive Biotechnologies Corporation $ADPT

Amova Asset Management Americas Inc. cut its holdings in Adaptive Biotechnologies Corporation (NASDAQ:ADPT) by 46.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,947,963 shares of the company’s stock after selling 1,702,683 shares during the period. Amova Asset Management Americas Inc.’s holdings in Adaptive Biotechnologies were worth $31,615,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. EverSource Wealth Advisors LLC boosted its holdings in Adaptive Biotechnologies by 197.1% in the fourth quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock worth $38,000 after purchasing an additional 1,565 shares in the last quarter. Assetmark Inc. boosted its holdings in Adaptive Biotechnologies by 867.9% in the fourth quarter. Assetmark Inc. now owns 3,020 shares of the company’s stock worth $49,000 after purchasing an additional 2,708 shares in the last quarter. Smartleaf Asset Management LLC boosted its holdings in Adaptive Biotechnologies by 593.5% in the third quarter. Smartleaf Asset Management LLC now owns 3,939 shares of the company’s stock worth $59,000 after purchasing an additional 3,371 shares in the last quarter. Clearstead Advisors LLC boosted its holdings in Adaptive Biotechnologies by 1,545.6% in the fourth quarter. Clearstead Advisors LLC now owns 3,752 shares of the company’s stock worth $61,000 after purchasing an additional 3,524 shares in the last quarter. Finally, Caxton Associates LLP bought a new stake in Adaptive Biotechnologies in the first quarter worth $93,000. 99.17% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on ADPT shares. JPMorgan Chase & Co. decreased their price target on shares of Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating for the company in a report on Wednesday, May 6th. Guggenheim restated a “buy” rating and set a $21.00 price target on shares of Adaptive Biotechnologies in a report on Wednesday, May 6th. TD Cowen upped their price target on shares of Adaptive Biotechnologies from $19.00 to $21.00 and gave the company a “buy” rating in a report on Wednesday, May 6th. BTIG Research restated a “buy” rating and set a $22.00 price target on shares of Adaptive Biotechnologies in a report on Wednesday, May 6th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a report on Monday, April 20th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $19.57.

Adaptive Biotechnologies Stock Performance

Shares of ADPT opened at $17.36 on Wednesday. The company has a 50-day simple moving average of $14.32 and a 200-day simple moving average of $15.66. The firm has a market capitalization of $2.78 billion, a P/E ratio of -52.61 and a beta of 2.15. Adaptive Biotechnologies Corporation has a 52 week low of $9.90 and a 52 week high of $20.76.

Adaptive Biotechnologies (NASDAQ:ADPT) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.03. The business had revenue of $70.87 million during the quarter, compared to analyst estimates of $61.03 million. Adaptive Biotechnologies had a negative net margin of 16.82% and a negative return on equity of 40.06%. The firm’s revenue for the quarter was up 35.1% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.20) earnings per share. As a group, equities analysts forecast that Adaptive Biotechnologies Corporation will post -0.47 earnings per share for the current year.

Insiders Place Their Bets

In other Adaptive Biotechnologies news, CEO Chad M. Robins sold 83,332 shares of the firm’s stock in a transaction dated Monday, April 6th. The shares were sold at an average price of $14.41, for a total transaction of $1,200,814.12. Following the completion of the transaction, the chief executive officer owned 2,217,781 shares in the company, valued at $31,958,224.21. This trade represents a 3.62% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Francis Lo sold 39,741 shares of the firm’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $17.49, for a total transaction of $695,070.09. Following the transaction, the insider owned 250,934 shares of the company’s stock, valued at approximately $4,388,835.66. This represents a 13.67% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 535,714 shares of company stock worth $7,756,708 over the last quarter. Company insiders own 5.70% of the company’s stock.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.